SHANGHAI RAAS BLOOD PRODUCTS CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.11 CNY | +1.14% |
|
-2.74% | -11.12% |
| 22/05 | Shanghai Raas Blood Products Co., Ltd. Approves 2023 Profit Distribution Plan | CI |
| 14/05 | GRIFOLS CEO SAYS CAN CONFIRM SHANGHAI RAAS TRANSACTION WILL CLO… | RE |
| Sales 2024 * | 8.73B 1.21B 100B | Sales 2025 * | 9.67B 1.33B 111B | Capitalization | 46.96B 6.48B 539B |
|---|---|---|---|---|---|
| Net income 2024 * | 2.1B 290M 24.11B | Net income 2025 * | 2.45B 338M 28.08B | EV / Sales 2024 * | 4.74 x |
| Net cash position 2024 * | 5.6B 773M 64.24B | Net cash position 2025 * | 8.58B 1.18B 98.42B | EV / Sales 2025 * | 3.97 x |
| P/E ratio 2024 * |
22.2
x | P/E ratio 2025 * |
19.2
x | Employees | 3,254 |
| Yield 2024 * |
0.21% | Yield 2025 * |
0.21% | Free-Float | 69.53% |
More Fundamentals
* Assessed data
More news
More news
| 1 day | +1.14% | ||
| 1 week | -2.74% | ||
| Current month | -0.97% | ||
| 1 month | -1.11% | ||
| 3 months | -0.42% | ||
| 6 months | -4.82% | ||
| Current year | -11.12% |
1 week
7.00
7.35
1 month
7.007.63
Current year
5.938.60
1 year
5.938.68
3 years
4.988.68
5 years
4.9811.16
10 years
4.9826.67
| Managers | Title | Age | Since |
|---|---|---|---|
Jun Xu
CEO | Chief Executive Officer | 60 | 01/12/01 |
Le Qi Chen
DFI | Director of Finance/CFO | 37 | 26/21/26 |
Wei Bing Hu
CHM | Chairman | 60 | 03/03/03 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 68 | 20/20/20 | |
Yue Wen Zheng
BRD | Director/Board Member | 62 | 27/07/27 |
David Bell
BRD | Director/Board Member | 70 | 20/20/20 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.71% | 2 M€ | -14.14% | ||
| 0.69% | 2 M€ | -17.92% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 27/24/27 | 7.11 | +1.14% | 26,795,820 |
| 24/24/24 | 7.03 | 0.00% | 25,606,970 |
| 23/24/23 | 7.03 | -1.54% | 31,735,130 |
| 22/24/22 | 7.14 | -2.46% | 45,612,840 |
| 21/24/21 | 7.32 | +0.14% | 27,390,280 |
End-of-day quote Shenzhen S.E., May 27, 2024
More quotes
Shanghai RAAS Blood Products Co., Ltd. specializes in the research, development and manufacturing of plasma-derived therapeutics. The group's products include human albumin, immunoglobulin and coagulation factors (thrombin, fibrinogen, prothrombin and fibrin).
China accounts for 96.6% of net sales.
Sector
Pharmaceuticals
Calendar
28/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
7.11
CNY
Average target price
6.55
CNY
Spread / Average Target
-7.88%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -11.12% | 6.48B | |
| -1.64% | 90.28B | |
| -0.66% | 39.5B | |
| -15.83% | 31.71B | |
| +62.42% | 26.41B | |
| -21.68% | 14.34B | |
| -8.73% | 12.89B | |
| -10.32% | 11.8B | |
| -45.77% | 10.95B | |
| +3.45% | 8.85B |
- Stock Market
- Equities
- 002252 Stock
